She underwent urgent T1 laminectomy with C5-T3 fusion, followed by systemic therapy with carboplatin/paclitaxel plus pembrolizumab, and later transitioned to carboplatin/etoposide. Histopathology confirmed small-cell NEC with squamous differentiation; expert review favored a poorly differentiated/dedifferentiated endometrial carcinoma with neuroendocrine and squamoid features. This case illustrates an atypical initial presentation with neurologic deficits from spinal metastases, emphasizing the need for prompt recognition and multidisciplinary management.

2 days ago

Journal • PD(L)-1 Biomarker

MUC16 (Mucin 16, Cell Surface Associated)

Keytruda (pembrolizumab) • carboplatin • paclitaxel • etoposide IV

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy (clinicaltrials.gov)

P3, N=670, Recruiting, Boehringer Ingelheim | Not yet recruiting --> Recruiting

2 days ago

Enrollment open

DLL3 (Delta Like Canonical Notch Ligand 3)

DLL3 expression

VENTANA DLL3 (SP347) Assay

Tecentriq (atezolizumab) • carboplatin • etoposide IV • obrixtamig (BI 764532)

Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma (clinicaltrials.gov)

P2, N=129, Active, not recruiting, Canadian Cancer Trials Group | Trial primary completion date: Mar 2026 --> Jun 2026

3 days ago

Trial primary completion date

CD20 (Membrane Spanning 4-Domains A1)

cisplatin • Imbruvica (ibrutinib) • gemcitabine • Rituxan (rituximab) • cyclophosphamide • etoposide IV • Xpovio (selinexor) • dexamethasone • mesna

Therapy for Children With Advanced Stage Neuroblastoma (clinicaltrials.gov)

P2, N=153, Completed, St. Jude Children's Research Hospital | Active, not recruiting --> Completed

6 days ago

Trial completion

MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)

MYCN amplification

cisplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • melphalan • mesna • Proleukin (aldesleukin) • busulfan • Unituxin (dinutuximab) • Leukine (sargramostim) • Neupogen (filgrastim) • daretabart (hu1418K322A)

Cyclophosphamide and Etoposide as a Metronomic Therapy in Advanced Head and Neck Squamous Cell Cancer (clinicaltrials.gov)

P2, N=120, Not yet recruiting, National Cancer Institute, Egypt | Initiation date: Jan 2026 --> Apr 2026

6 days ago

Trial initiation date

cyclophosphamide • etoposide IV

Rux-cALL-Pol 2020: Single-arm interventional study with ruxolitinib and AIEOP-BFM 2017 Poland or AIEOP-BFM 2017 standard of care chemotherapy in children with acute lymphoblastic leukemia and confirmed activation of JAK/STAT pathway. (2024-518316-39-00)

P2/3, N=25, Recruiting, Medical University Of Lodz | Not yet recruiting --> Recruiting

7 days ago

Enrollment open

JAK2 (Janus kinase 2) • RUNX1 (RUNX Family Transcription Factor 1) • KMT2A (Lysine Methyltransferase 2A) • ETV6 (ETS Variant Transcription Factor 6) • CRLF2 (Cytokine Receptor Like Factor 2) • IKZF1 (IKAROS Family Zinc Finger 1) • AFF1 (AF4/FMR2 Family Member 1) • TCF3 (Transcription Factor 3) • PBX1 (PBX Homeobox 1)

KMT2A rearrangement

cytarabine • doxorubicin hydrochloride • Jakafi (ruxolitinib) • cyclophosphamide • ifosfamide • etoposide IV • vincristine • daunorubicin • Oncaspar liquid (pegaspargase) • mercaptopurine • thioguanine • vindesine

ZUMA-23: Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma (clinicaltrials.gov)

P3, N=300, Active, not recruiting, Kite, A Gilead Company | Recruiting --> Active, not recruiting

7 days ago

Enrollment closed

Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • Yescarta (axicabtagene ciloleucel) • prednisone • fludarabine IV

Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant (clinicaltrials.gov)

P1, N=53, Suspended, City of Hope Medical Center | Recruiting --> Suspended

7 days ago

Trial suspension

HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)

cyclophosphamide • etoposide IV • sirolimus • Kepivance (palifermin)

ALK-Negative Systemic Anaplastic Large Cell Lymphoma With Multifocal Cutaneous Involvement Responding to Brentuximab Vedotin. (PubMed, Am J Dermatopathol)

After a dose of ifosfamide/etoposide elsewhere, therapy was revised to ifosfamide, carboplatin, and etoposide plus brentuximab vedotin, with marked improvement by 2 cycles and cutaneous resolution by 5; she died of cardiopulmonary failure before the sixth cycle. This case underscores generous sampling, focused immunohistochemistry, and staging; negative ALK/EMA does not exclude systemic disease, and CD30-directed therapy can yield rapid cutaneous responses.

8 days ago

Journal

ALK (Anaplastic lymphoma kinase) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C)

ALK positive • LDH elevation • ALK negative

carboplatin • ifosfamide • etoposide IV • Adcetris (brentuximab vedotin)

DAREON-8: DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer (clinicaltrials.gov)

P1, N=46, Active, not recruiting, Boehringer Ingelheim | Trial completion date: Sep 2026 --> Apr 2027

8 days ago

Trial completion date

Tecentriq (atezolizumab) • carboplatin • etoposide IV • obrixtamig (BI 764532)

Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma (clinicaltrials.gov)

P2, N=26, Active, not recruiting, M.D. Anderson Cancer Center | N=40 --> 26 | Recruiting --> Active, not recruiting

8 days ago

Enrollment closed • Enrollment change

carboplatin • ifosfamide • etoposide IV • mesna

RYZ101-101: Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC (clinicaltrials.gov)

P1, N=21, Active, not recruiting, RayzeBio, Inc. | N=49 --> 21 | Trial completion date: Mar 2029 --> Jul 2027 | Recruiting --> Active, not recruiting

9 days ago

Enrollment closed • Enrollment change • Trial completion date

PD-L1 (Programmed death ligand 1) • SSTR (Somatostatin Receptor)

Tecentriq (atezolizumab) • carboplatin • etoposide IV • Actinium-225 DOTATATE (RYZ101)